3-dimethylaminovinylene-4-nitropyridine-l-oxide | 104118-88-9

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 3-dimethylaminovinylene-4-nitropyridine-l-oxide
• 英文别名: 3-[2-(Dimethylamino)vinyl]-4-nitropyridine 1-Oxide；N,N-dimethyl-2-(4-nitro-1-oxidopyridin-1-ium-3-yl)ethenamine
• CAS: 104118-88-9
• 化学式: C₉H₁₁N₃O₃
• mdl: MFCD11100905
• 分子量: 209.205
• InChiKey: FGBBTNYRURUPDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  74.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-dimethylaminovinylene-4-nitropyridine-l-oxide 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 20.0~65.0 ℃ 、300.01 kPa 条件下， 反应 8.0h， 以74.5%的产率得到5-氮杂吲哚
  参考文献：
  名称：

  Novel 3-Azaindolyl-4-arylmaleimides Exhibiting Potent Antiangiogenic Efficacy, Protein Kinase Inhibition, and Antiproliferative Activity

  摘要：

  Tumor growth and metastasis are highly associated with the overexpression of protein kinases (PKs) regulating cell growth, apoptosis resistance, and prolonged cell survival. This study describes novel azaindolyl-maleimides with significant inhibition of PKs, such as VEGFR, FLT-3, and GSK-3 beta which are related to carcinogenesis. Furthermore, these compounds exhibit high kinase selectivity and potent inhibition of angiogenesis and cell proliferation, offering versatile options in cancer treatment strategies.

  DOI：

  10.1021/jm301217c
• 作为产物：
  描述：

  3-甲基吡啶氧化物 在 硫酸 、 硝酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 3-dimethylaminovinylene-4-nitropyridine-l-oxide
  参考文献：
  名称：

  Novel 3-Azaindolyl-4-arylmaleimides Exhibiting Potent Antiangiogenic Efficacy, Protein Kinase Inhibition, and Antiproliferative Activity

  摘要：

  Tumor growth and metastasis are highly associated with the overexpression of protein kinases (PKs) regulating cell growth, apoptosis resistance, and prolonged cell survival. This study describes novel azaindolyl-maleimides with significant inhibition of PKs, such as VEGFR, FLT-3, and GSK-3 beta which are related to carcinogenesis. Furthermore, these compounds exhibit high kinase selectivity and potent inhibition of angiogenesis and cell proliferation, offering versatile options in cancer treatment strategies.

  DOI：

  10.1021/jm301217c

文献信息

• HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20140155398A1

  公开（公告）日：2014-06-05

  The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R 1 , R 2 and R 3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

  本发明提供了一种异环化合物，其化学式为（I），其药学上可接受的盐，其前药或水合物，其中A，A'，B，D，R1，R2和R3如本文所定义，包括一种以化合物（I）为活性成分的药物组合物，生产方法以及使用方法。特别是，本发明提供了一种化合物（I），用于治疗或预防与蛋白激酶相关的疾病，症状或紊乱，优选为Janus激酶家族。
• [EN] HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：DAIICHI SANKYO CO LTD

  公开号：WO2012160464A1

  公开（公告）日：2012-11-29

  The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A' B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

  本发明提供了一种异环化合物的化学式(I)，其药学上可接受的盐，其前药或水合物，其中A，A'，B，D，R1，R2和R3如本文所定义，包括一种化合物的药物组合物的化学式(I)作为活性成分，生产方法和使用方法。特别是，本发明提供了一种化合物的化学式(I)，用于治疗或预防与蛋白激酶相关的疾病，症状或紊乱，优选为Janus激酶家族。
• NOVEL COMPOUNDS
  申请人：Gottschling Dirk

  公开号：US20110021500A1

  公开（公告）日：2011-01-27

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 , R 3 and R 4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

  本发明涉及一般式I的新的CGRP拮抗剂，其中U、V、X、Y、R1、R2、R3和R4如描述中所定义，其互变异构体、同分异构体、对映异构体、立体异构体、水合物、其混合物及其盐以及盐的水合物，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物、它们的用途以及制备它们的方法。
• Rearrangement of Nitropyridylidenemalonate 1-Oxides. A Novel Method for the Synthesis of Aminopyridine Derivatives
  作者：Stanislaw F Wnuk、Elzbieta Lewandowska、Carlos A Valdez、Stefan Kinastowski

  DOI：10.1016/s0040-4020(00)00693-1

  日期：2000.9

  and diethyl malonate catalyzed by titanium(IV) chloride gave diethyl 3-nitro-2-pyridylidenemalonate which was oxidized with peracetic acid to give corresponding 1-oxide. Reaction of the latter with diethylamine in the presence of primary and secondary alcohols resulted in the reduction of the nitro group and the oxidation of the vinylic carbon attached to the pyridine ring. Simultaneous migration of

  氯化钛（IV）催化3-硝基-2-吡啶甲醛与丙二酸二乙酯之间的Knoevenagel缩合反应，得到3-硝基-2-吡啶基亚甲基丙二酸二乙酯，将其用过乙酸氧化，得到相应的1-氧化物。在伯醇和仲醇的存在下后者与二乙胺的反应导致硝基的还原和与吡啶环相连的乙烯基碳的氧化。丙二酸片段的同时迁移得到合适的3-氨基-2-吡啶羧酸酯。4-硝基-3-吡啶基亚甲基丙二酸酯1-氧化物重排成相应的4-氨基-3-吡啶羧酸酯类似物。
• AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
  申请人：BERNOTAS Ronald Charles

  公开号：US20080114023A1

  公开（公告）日：2008-05-15

  The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

  本发明提供一种公式I的化合物以及其在治疗与或受5-HT6受体影响的疾病方面的应用。